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Summary 
Indefinite  graft  survival  was  obtained  with  murine  cardiac  allografts  using  the  combined 
administration  of monoclonal  antibodies  (mAbs)  directed  against  the  receptor  ligand  pair 
CD2-CD48.  Although each antibody could prolong graft survival when given alone, neither 
resulted in the indefinite graft survival seen with the combination. Combined mAb administration 
is associated with inhibition of T cell priming and help and subsequent cytotoxic T lymphocyte 
generation. This indicates  that the interaction between CD2 and its ligand is important for antigen 
priming  and recognition,  and combined mAbs may prove to be a useful therapeutic regimen 
for transplantation. 
T 
olerance induction is the major goal in transplantation. 
It has been obtained with several regimens including the 
administration of pairs of mAbs to CD4 and CD8 (1), CD2 
and CD3 (2), and CDlla/CD18  and CD54 (3). The com- 
bined use of antireceptor plus antiligand  mAbs may be ad- 
vantageous in blocking both T cells and APCs, and in blocking 
interactions  with as yet unknown ligands.  Recent findings 
have identified murine CD48 (4), and human CD59 (5, 6), 
and sulfated carbohydrates (7) as potential ligands for CD2, 
in addition  to the well-characterized  human  ligand  CD58 
(LFA-3). Murine CD48 (Blast-I, BCM1) has structural ho- 
mology to human CD58, including glycosyl-phosphatidylino- 
sitol linkage to the cell membrane,  and functions in signal 
transduction and activation of lymphoid cells (4, 8-10). CD2 
is important in adhesion and signal transduction (11, 12), and 
anti-CD2  mAbs suppress cell-mediated immunity  (13,  14) 
and prolong allograft and xenograft survival (15). With the 
recent availability  of mAbs defining this receptor-ligand pair, 
the combination of anti-CD2 plus anti-CD48 mAbs was ad- 
ministered in a murine cardiac allograft model and indefinite 
graft survival was observed. The induction of indefinite graft 
survival is associated with inhibition  of T  cell priming and 
help and subsequent CTL generation, while maintenance of 
tolerance is associated with a lack of T  cell help. This indi- 
cates that  CD2-CD48  interactions  and signals  are integral 
to antigen priming  and recognition,  and combined mAbs 
are  an important  therapeutic  regimen  for transplantation. 
Materials and Methods 
Animals.  CBA/J (H-2  k) and BALB/cByJ (H-2  d) female mice, 
8-10-wk-old,  were purchased from The Jackson Laboratory (Bar 
Harbor, ME). Timed pregnant C57BL/6 (H-2  b) and BALB/c mice 
were purchased from Harlan Sprague Dawley, Inc. (Indianapolis, 
IN) and were used as the donor strains. 
Reagents.  The 12-15 rat IgG1 anti-routine CD2 hybridoma (16), 
a gift of Dr. Peter Ahevogt (Immunology and Genetics Institute, 
Heidelberg,  Germany),  and the HM48-1 hamster  IgG anti-mu- 
rine CD48 (4) were grown in culture  and purified over protein 
G (Pharmacia, Piscataway, NJ).  For control mAbs the YTS-259 
rat IgG1 anti-ras (17) was used. Abs were injected intravenously 
in PBS or were used in vitro at specified concentrations. 
Cardiac Transplantation.  Donor embryonic (E 18-21) or neonatal 
(P 1-2) C57BL/6 or BALB/c mice were killed, whole hearts re- 
moved, and placed in a subcutaneous pocket in the ear pinnae of 
CBA/J recipients as previously described (15, 18, 19). Survival of 
allografts was followed by EKG monitoring (Polygraph 78 Series 
with preamp and filters; Grass Instruments Co., Quincy, MA) every 
other day. Cessation of cardiac electrical activity was the determinant 
of rejection. Statistical comparison of results is with Wilcoxon Sign 
Rank. Recipients received  intravenous injections ofmAbs in 0.5-ml 
volumes of PBS at specified times. 
Cytotoxic T Lymphocytes.  Spleens  were removed and gently dis- 
sociated into single cell suspensions. Red blood cells were removed 
from responder cell populations  by centrifugation  over a Ficoll 
(Sigma Chemical Co., St. Louis, MO) -Metrizoate (Nycomed Phar- 
maceuticals, Oslo, Norway) discontinuous gradient (specific  gravity 
1.09, 24~  15 min, 1,200 g). Red blood cells were removed from 
stimulator  cells by Tris-NH4C1 lysis. The CTL culture  and assay 
were performed as described previously (13). Responders and stimu- 
lators were placed in culture  and harvested after 7 d. A standard 
4-h, Cr  51 release assay was performed in triplicate wells. Control 
always included irrelevant targets (P815 or EL-4) and were always 
~<5% specific lysis. Spontaneous release was 5-15% of total incor- 
porated counts. CTL generated by this protocol were CD8 +  , H-2 
restricted, and antigen specific with peak alloantigen-specific, pri- 
mary CTL responses (CBA/J anti-B6 or CBA/J anti-BALB/c) noted 
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(experimental  -  spontaneous)/(100% lysis -  spontaneous). The 
SEM was  always ~<2%. 
Mixed  LymFhocyte Reaction.  2  x  105 responder  spleen  cells 
were cocultured in triplicate with 2  x  10  s 1,500-tad y-irradiated 
stimulator cells for 5 d. 18 h before termination of cuhure the wells 
were pulsed with 0.5 #Ci of [3H]thymidine and incorporation was 
quantitated on a scintillation counter. Results are expressed as mean; 
SEM g5%. 
Mitogen-induced Proliferation Assays.  Splenic lymphocytes were 
isolated by mechanical dissociation and Tris-NH4C1 lysis of red 
blood  cells,  and  plated  at  10  s  cells  in  200-/A  96-well  round- 
bottomed plates.  Con A and PHA were added to 5/~g/ml. Anti- 
CD3 mAb (2Cll) was coated onto wells in 50/zl at 10 #g/ml. 
mAbs were each added to culture to 5/zg/ml. Cultures were in- 
cubated for 72 h,  pulsed with  [3H]TdR for the last  18 h,  har- 
vested, and counted. Data are expressed as mean counts per minute 
of triplicate samples; SEM ~<5%. For separate CD4 and CD8 popu- 
lations,  splenic  T  lymphocytes were enriched over nylon wool 
columns and separated on antibody columns (g & D Systems, Min- 
neapolis,  MN)  according  to  manufacturer's  instructions.  After 
column separation,  flow cytometric analysis showed <1% contam- 
ination of responder cell population with the opposite T cell subset. 
Cytokine Assays.  Culture supernatants from 4-d alloantigen- 
stimulated cultures were harvested and tested for IL-2 in the CTL-L 
assay (20) or for IL-4 in the HT-2 assay (21). Standard curves were 
run concurrently with rmlL-2 or rmlL4 (Genyzme, Cambridge, 
MA). 
Results  and  Discussion 
Animals receiving anti-CD2 mAb alone had graft survival 
of 24.4  _+  1.0 d, and those receiving anti-CD48 mAb alone 
had  graft  survival  of  19.9  _+  0.6  d.  These  were  mildly 
prolonged and significantly different (p <0.05) from control 
animals receiving no mAb, or control mAb, which rejected 
allografts by 13.4  +_  0.5 d. However, animals that received 
the combination of anti-CD2 plus anti-CD48 mAbs showed 
prolongation  of graft  survival for >100  d  (Fig.  1).  These 
animals  showed no apparent toxic side effects and no mor- 
tality associated with the mAb regimen. Dose-response and 
kinetic data showed 100 #g of mAb to be the maximal and 
optimal dose for immunosuppression and that mAb had to 
be administered  at  the  time of transplantation  (3,  15,  and 
our unpublished results). A delay in administration with re- 
spect to transplantation by a few days was not effective. Thus 
the mAbs were more effective as prophylactic than therapeutic 
reagents. 
Since CTLs are a major effector arm of graft rejection, CTL 
cultures were used to probe the mechanism of tolerance in- 
duction and the level at which the combination ofmAbs was 
acting. Previous work showed that anti-CD2 and anti-CD48 
mAbs can inhibit the priming of CTL in vivo (13 and our 
unpublished observations). Therefore, additional experiments 
focused on the effects of the mAbs in vitro. The mAbs were 
added at  the initiation  of primary allogeneic CTL culture 
or at the time of CTL assay.  The doses of mAbs used were 
known  to  be  saturating  from  previous  experiments  (not 
shown). Both anti-CD2  and anti-CD48 mAbs partially in- 
hibited the generation  of CTL activity when  added alone 
to culture (Table 1). However, when combined, CTL induc- 
tion was completely inhibited. The mAbs had minimal effect 
alone, or in combination, when added 7 d later to the CTL 
lytic assay. These results show that interference with receptor- 
ligand interactions at the time of priming is an essential com- 
ponent for tolerance induction. This suggests that the mAbs 
interfere more with T  cell helpers or CTL precursors than 
with  cytotoxic effectors. 
Since proliferative responses are often considered a reflec- 
tion of normal immunity, the combination of mAbs was also 
Table  1.  Anti-CD2 Plus Anti-CD48 mAbs Inhibit CTL 
Stimulation Cultures but Not the Lyric Assay 
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Figure  1.  Survival  of cardiac allografts. C57BL/6 neonatal hearts were 
transplanted into CBA/J mice. Recipient mice (seven/group)  were injected 
intravenously with either 100/zg of anti-CD2, isotype control mAb, or 
anti-CD48 alone or in combination at the time of allografting (day 0) 
and on day I after transplantation. Survival  time of the combined regimen 
was significantly  greater (p <0.001) than either mAb alone  or control mAb. 
mAb added to: 
Percent specific 
cytotoxicity 
(E/T ratio) 
100:1  30:1  10:1 
Stimulation culture 
Lytic assay 
-  68.5  54.9  42.4 
c~CD2  45.1  31.2  18.9 
aCD48  18.9  9.6  3.0 
oeCD2/aCD48  2.5  4.4  0 
-  71.8  63.1  58.9 
cr  74.0  60.0  52.2 
otCD48  74.9  55.6  49.5 
c~CD2/~CD48  70.4  57.1  54.7 
BALB/c splenic  lymphocytes  were placed  in culture with C57BL/6 stimu- 
lators for 7 d. Anti-CD2, anti-CD48, or the combination of mAbs were 
added at the initiation of culture, or at the time of assay, at a concentra- 
tion of 5 #g/ml. Similar data were obtained with CBA/J responder cells. 
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mAbs 
Cells  Mitogen  Control mAb  c~CD2  cr  c~CD2/~CD48 
CD4 + 
CD8 + 
cpm 
-  409  273  308  278 
Con A  37,391  14,707  7,656  20,300 
PHA  15,092  5,480  4,353  4,950 
c~CD3  78,937  92,838  69,047  67,523 
MLR  57,680  60,536  36,820  38,058 
-  315  261  122  364 
Con A  19,184  14,270  14,481  14,844 
PHA  21,905  9,025  4,968  6,229 
cr  33,864  34,716  23,422  25,971 
MLR  11,447  9,391  9,906  10,680 
BALB/c splenic  lymphocytes  were stimulated with the indicated mitogen as described  in Materials and Methods. C57BL/6 was the stimulator in MLK. 
assessed for its ability to block mitogen-induced T cell prolifer- 
ation. The mAbs partially inhibited in vitro proliferative re- 
sponses to Con A, PHA, MHC alloantigen, and anti-CD3 
mAb in CD4 + and CD8 + splenic lymphocytes (Table  2). 
For  CD4 §  cells,  anti-CD2  did  not  inhibit  anti-CD3  or 
alloantigen-driven proliferation, while anti-CD48 had a mar- 
ginal effect on anti-CD3-induced proliferation and a more 
significant effect on alloantigen-induced proliferation. For 
CD8 +  cells,  anti-CD2  again  did  not  inhibit  anti-CD3- 
driven proliferation, while anti-CD48 was effective in this 
regard. Both mAbs effectively inhibited CD4 § and CD8 § 
responses to both Con A and PHA. This demonstrates that 
these antibodies can affect responsiveness of both major T 
cell subsets via multiple different activation pathways which 
may (alloantigen, anti-CD3) or may not (Con A, PHA) de- 
pend on direct T  cell receptor stimulation. These mitogens 
are, however, all antigen-presenting cell dependent with the 
culture conditions used (22-24), and this may be a determinant 
of mAb inhibition. As a correlate to inhibition of mitogen- 
or alloantigen-driven proliferation, supernatants from these 
stimulation cultures were harvested and assayed for cytokine 
content. The results in Table 3 show that CD8 § cells pro- 
duce little cytokine in response to alloantigen and that anti- 
CD2 and/or anti-CD48 mAbs have little effect on these levels. 
Conversely, CD4 § cells produce both IL-2 and IL-4 in re- 
sponse to alloantigen, and cytokine production is inhibited 
by both mAbs.  In general, anti-CD48 is more effective in 
this regard than anti-CD2,  and the combination of mAbs 
is at least additive in its inhibitory effect. Assays for IL-10 
and TGF-/3 showed no changes as a result of mAb treatment 
of separated  or  unseparated  cells  (not  shown).  For  anti- 
CD3-stimulated cultures, neither anti-CD2 nor anti-CD48 
inhibited IL-2 or IL-4 production by CD4 + or CD8 § sub- 
sets (not shown), which parallels the findings with the prolifer- 
ative responses in Table 2.  Therefore the mAbs inhibit the 
alloantigen-stimulated production of helper-derived cytokines 
responsible for driving effector proliferation and maturation. 
To evaluate the maintenance of the tolerant state,  animals 
with long-term surviving grafts received a second donor- 
specific graft of the identical H-2 type to the contralateral 
ear pinna. Surprisingly, rejection of both the first and second 
grafts ensued at 10.0 +  1.0 d. This indicated that maintenance 
of the tolerant state most likely was not due to clonal dele- 
tion, suppression, or graft adaptation. Previous flow cytom- 
etry data showed that these mAbs do not deplete T  cells, 
Table 3.  Anti-CD2 Plus Anti-CD48 mAbs Inhibit 
Alloantigen-Stimutated IL-2 and IL-4 Production 
Cells  mAb 
Cytokine response 
IL-2  IL-4 
CD8 + 
CD4 § 
U/ml 
Control mAb  3.0  0 
otCD2  2.4  0 
c~CD48  1.2  0 
c~CD2/c~CD48  1.0  0 
Control mAb  19.8  3.2 
c~CD2  14.0  0.9 
otCD48  6.4  0 
otCD2/c~CD48  2.8  0 
Day 4 MLR culture supernatants from unseparated or separated cell sub- 
sets were assayed for cytokine content. 
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or CD48 without affecting CD3, CD4, or CD8 expression 
(3, 13, 14, and our unpublished observations). Therefore, these 
data suggest that anergy or alterations in T cell populations 
at the time of initial antigen and mAb exposure result in 
indefinite graft survival.  In particular the data demonstrate 
that effector cells or their precursors are present and there- 
fore suggest that effective T  cell help is lacking. The data 
in Table 3 showing inhibition of cytokine production sup- 
port this notion further. Furthermore, this effect was antigen 
specific since CBA recipients that tolerated a first C57BL/6 
graft for >60 d rejected a third party BALB/c graft in a first 
set fashion (12.0 _+ 0.6 d) while maintaining the first C57BL/6 
graft intact. To test this hypothesis further, CTL activity was 
measured in recipients of either one or two allografts. Splenic 
lymphocytes from animals that had received anti-CD2 mAb 
alone and had rejected a single allograft showed normal CTL 
activity to both donor H-2-specific (Table 4) and third party 
target cells (not shown). Lymphocytes from animals treated 
with the combination anti-CD2 plus anti-CD48 mAbs, which 
had initially accepted a first graft but had subsequently re- 
jected both first and second grafts after a second transplant, 
also showed normal donor-specific and third party CTL ac- 
tivity. Likewise, lymphocytes from animals treated with the 
combination of mAbs, and which retained one long-term sur- 
viving graft, also  showed normal donor-specific and third 
party CTL activity. Similarly the mixed lymphocyte prolifer- 
ative responses  were essentially the same for all groups, or 
even slightly augmented in the group retaining its single graft. 
The presence of CTL precursors,  and the ability to stimulate 
the response by regrafting, suggest that tolerance is main- 
tained by a lack of effective T  cell help in vivo.  This help 
could be generated by restimulation with lymphocytes  in vitro 
or a second graft in vivo. 
The combination of anti-CD2 and anti-CD48 mAbs is able 
to induce indefinite graft survival. Although each mAb alone 
can induce immune suppression,  each does not result in the 
same state of long-term graft survival seen with the combi- 
nation. The mechanism of induction is related to inhibition 
of initial priming to antigen. The CTL (Table 1), prolifera- 
tive (Table 2), and cytokine data (Table 3) indicate that inhi- 
bition affects both precursor CTL and helper cells. It is not 
clear if the mechanism of tolerance induction is related to 
direct signaling effects of the mAbs themselves  on T  cells, 
to blocking of CD2-CD48 receptor-ligand interactions, or 
to inhibition of interactions of these molecules with other 
potential ligands (5-7). These are not mutually exclusive  mech- 
anisms and all may be important. Since anti-CD2 and anti- 
CD48 induce long-term graft survival in the putative absence 
of blockade  of other  receptor-ligand  pairs  (e.g.,  LFA-1- 
ICAM-1, CD28-B7), this suggests that some sort of"nega- 
tive" signal is generated by mAb or receptor blockade that 
subsequently inhibits second messenger pathways of alterna- 
tive coreceptors. Since CD2-knockout mice (25) are immuno- 
logically intact, the results here support a signaling role for 
mAb. Anti-CD2 also impairs NK function (15) and this may 
further contribute to inductive effects. 
While our results indicate that reduced T  cell help may 
be responsible  for indefinite graft survival, they do not indi- 
cate how this reduction is maintained long term. It may be 
considered that at the time of initial grafting both class I 
and class II MHC and other costimulatory molecules are ex- 
Table  4.  Tolerant Recipients Can Generate Normal CTL and MLR Activity 
In vivo treatment  Cardiac transplant  Rejection 
Percent specific cytotoxicity 
(E/T ratio) 
Target  100:1  30:1  10:1 
CTL 
MLR 
o~CD2  x 1  +  EL-4(H-2  b)  72.4  65.6  43.4 
c~CD2/aCD48  x 2  +  73.2  67.9  59.1 
t~CD2/o~CD48  x 1  -  60.0  47.6  36.1 
Stimulator 
_  H.2  b  H-2  d 
-  x 1  +  1,823  16,805  16,869 
cxCD2  x 1  +  4,620  17,861  16,727 
c~CD2/aCD48  x 2  +  6,720  28,925  36,070 
c~CD2/c~CD48  x 1  -  4,701  37,273  35,185 
CBA/J recipients were originally  transplanted with C57BL/6 and received 100 #g anti-CD2 or 100 #g anti-CD2 plus 100/zg anti-CD48 on days 
0 and 1 after transplantation. Recipients were retransplanted without further immunosuppression 100 d after the initial transplant, and killed at 
least 60 d after the first or second transplant. Splenic lymphocytes  were stimulated  in culture with donor-specific  (C57BL/6) or third party (BALB/c) 
splenocytes and CTL or MLR activity  was assayed. CTL responses of untransplanted  or transplanted and untreated  recipients  were similar to those 
of the anti-CD2-treated recipients (not shown). 
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events (26-28). Anti-CD2 plus anti-CD48 may interfere with 
the priming of helpers and generation of effectors at this stage. 
As initial inflammation wanes, class II MHC and costimula- 
tory molecule expression disappear,  resulting in a graft that 
expresses class I MHC but is unable to generate effective  help. 
A second graft would express costimulators and provide effec- 
tive help in this situation.  Likewise, the allogeneic stimu- 
lator lymphocytes used in culture may also provide effective 
costimulatory help in vitro for MLR and CTL responses. 
The approach of combined mAbs may prove to be an impor- 
tant regimen for induction therapy for allografting.  The results 
here and elsewhere (1-3) may imply that the complete inhi- 
bition of a single receptor-ligand pair with a combination 
of mAbs is enough to abrogate the stimulatory effects of other 
coreceptors. This may be achieved because receptors are more 
completely blockaded by this regimen. Alternatively, because 
many of these receptor-ligand pairs  are coexpressed on the 
same cell, the combination of mAbs may be providing more 
potent negative signals  than single mAbs at the individual 
cell level. 
We thank  Dr. Peter Altevogt for the 12-15 mAb and Vicki Graham for expert secretarial assistance. 
This work was supported by a Biomedical Research Support Grant from Medical University of South 
Carohna; Procept, Inc., Cambridge, MA; the American Surgical Association Foundation Fellowship Award; 
and National  Institutes  of Health  grant AI-32655. 
Address correspondence to Dr. Jonathan S. Bromberg, Transplant Program, 404 CSB, Medical University 
of South Carolina,  171 Ashley Avenue, Charleston,  SC 29425. 
Received for publication  8 July  1993  and in revised form 20 October 1993. 
References 
1.  Qin, S., S. Cobbold, R. Benjamin, and H. Waldmann. 1989. 
Induction of classical transplantation  tolerance in the adult. 
J. Exp. Med. 169:779. 
2.  Isobe, M., H. Yagita, K. Okumura, and A. Ihara. 1992. Specific 
acceptance of cardiac allograft after treatment with antibodies 
to ICAM-1 and LFA-1. Science (Wash. DC). 255:1125. 
3.  Chavin, K.D., L. Qin, J. Lin, A.J. Kaplan, and J.S. Brom- 
berg. 1993. Anti-CD2 and anti-CD3  monoclonal antibodies 
synergize to prolong allograft  survival with decreased side 
effects. Transplantation (Baltimore). 55:901. 
4.  Kato, K., M. Koyanagi, H. Okada, T. Takanashi, Y.W. Wong, 
A.F. Williams, K. Okumura, and H. Yagita. 1992. CD48 is 
a counter-receptor for mouse CD2 and is involved in T cell 
activation, j. Ex  F  Med. 176:1241. 
5.  Hahn, W.C.,  E. Menu,  A.L. Bothwell, P.J. Sims, and B.E. 
Bierer. 1992. Overlapping but nonidentical binding  sites on 
CD2 for CD58 and a second ligand CD59. Science (Wash. DC). 
256:1805. 
6.  Deckert, M., J. Kubar, D. Zoccola, P.G. Bernard, P. Angelisova, 
V. Horejsi, and A. Bernard. 1992. CD59 molecule: a second 
ligand of CD2 in T cell adhesion. Eur. J. Immunol. 22:2943. 
7.  Warren, H.S., and C.R. Parish. 1990. Mapping the dextran 
sulfate binding  site on CD2. Immunol. Cell Biol. 68:199. 
8.  Kato, K., N.  Tamura, K.  Okumura,  and H. Yagita. 1993. 
Identification of a T cell surface signal-transducing glycopro- 
tein,  sgp-60, as CD48 that is a counter-receptor  for mouse 
CD2. Eur. J. lmmunoL In press. 
9.  Maschek, B.J., W. Zhang, P.M. Rosoff, and H. Reiser. 1993. 
Modulation of the intercellular Ca  z§ and inositol triphosphate 
concentrations in murine T lymphocytes by glycosylphospha- 
tidylinositol-anchored protein sgp-60. J. Immunol. 150:3198. 
10.  Cabrero, J.G., G.J. Freeman, W.S. Lane, and H. Reiser. 1993. 
Identification by protein sequencing and gene transfection, of 
sgp-60 as the routine homologue of CD48. Proc. Natl. Acad. 
Sci. USA.  90:3418. 
11.  Moingeon, P., H.C. Chang, P.H. Sayre, L.K. Clayton, A. A1- 
cover, P. Gardner, and E.L. Reinherz.  1989. The structural 
biology of CD2. Immunol. Rev. 111:111. 
12.  Bierer, B.E., and S.J. Burakoff. 1989. T-lymphocyte  activation: 
the biology and function  of CD2 and CD4. Immunol. Rev. 
111:267. 
13.  Bromberg, J.S., K.D. Chavin, P. Altevogt, B.A. Kyewski, B. 
Guckel, A. Naji, and C.F. Barker. 1991. Anti-CD2 monoclonal 
antibodies alter cell-mediated immunity in vivo. Transplanta- 
tion (Baltimore). 51:219. 
14.  Gfickel, B., C. Berek, M. Lutz, P. Altevogt, V. Schirrmacher, 
and B.A. Kyewski. 1991. Anti-CD2 antibodies induce T cell 
unresponsiveness in vivo. J. Exp. Med. 174:957. 
15.  Chavin, K.D., H.T. Lau, andJ.S. Bromberg. 1992. Prolonga- 
tions of allograft and xenograft survival in mice by anti-CD2 
monoclonal antibodies. Transplantation (Baltimore). 54:286. 
16.  Altevogt, P., U. Kohl, H.P. Von, E. Lang, and V. Schirrmacher. 
1989. Antibody  12-15 cross-reacts with  mouse  Fc gamma 
receptors and CD2: study of thymus expression, genetic poly- 
morphism and biosynthesis of the CD2 protein. Eur. J. Im- 
munol. 19:341. 
17.  Furth, M.E., L.J. Davis, B. Fleurdelys,  and E.M. Scolnick. 1982. 
Monoclonal antibodies to the p21 products of the transforming 
gene of Harvey murine sarcoma virus and of the cellular ras 
gene family.  J.  Virol. 43:294. 
18.  Fulmer, R.I., A.T. Cramer, and A.G. Liebelt. 1963. Transplan- 
tation of cardiac tissue into mouse ear. Am. J. Anat.  113:273. 
19. Judd, K.P., and J.J. Trentin. 1971. Cardiac transplantation in 
mice. I. Factors influencing the take and survival of hetero- 
topic grafts. Transplantation (Baltimore). 11:298. 
20.  Baker, RE., S. Gillis, and K.A. Smith. 1979. Monoclonal cyto- 
345  Qin et al.  Brief  Definitive Report toxic T-cell lines. J. Exp. Med.  149:273. 
21.  Watson, J. 1979. Continuous proliferation ofmurine antigen- 
specific helper T lymphocytes in culture.J. Exp. Med. 150:1510. 
22.  Lipsky, P.E., J.J.  Ellner,  and A.L.  Rosenthal.  1976. Phyto- 
hemagglutinin-induced proliferation of guinea pig thymus- 
derived lymphocytes. I. Accessory cell dependence.J. Immunol. 
116:868. 
23.  Hoffmann, M.K., M. Chun, andJ.A. Hirst. 1986. Conditional 
requirement for accessory cells in the response of T  cells to 
Con A. Lymphokine Res.  5:1. 
24.  Bekoff, M.,  R.  Kubo, and H.M. Grey.  1986. Activation re- 
quirements for normal T  cells: accessory cell-dependent and 
-independent stimulation by anti-receptor antibodies. J. Im- 
rnunol. 23:46. 
25.  Killeen,  N., S.G. Stuart, and D.R. Littman. 1992. Develop- 
ment and function of T cells in mice with a disrupted CD2 
gene. EMBO (Eur. Mol. Biol. Organ.) J.  11:4329. 
26.  Jutila, M.A., E.L. Berg, T.K. Kishimoto, L.J. Picker, R.F. Bar- 
gatze, D.K. Bishop, C.G. Orosz, N.W. Wu, and E.C. Butcher. 
1989. Inflammation-induced endothelial cell adhesion to lym- 
phocytes, neutrophils, and monocytes. Role of  homing receptors 
and other adhesion molecules. Transplantation  (Baltimore). 48:727. 
27.  Springer, T.A. 1990. Adhesion receptors of the immune system. 
Nature (Lond.). 346:425. 
28.  Shimizu, Y., and S. Shaw. 1991. Lymphocyte interactions with 
extracellular matrix. FASEB (Fed. Am. Soa Extx Biol.)J. 5:2292. 
346  Anti-CD2 Plus Anti-CD48 Induce Tolerance 